Fate Therapeutics, Inc. (FATE)
| Market Cap | 214.47M +95.3% |
| Revenue (ttm) | 6.32M -52.6% |
| Net Income | -129.91M |
| EPS | -1.09 |
| Shares Out | 116.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,878,429 |
| Open | 1.870 |
| Previous Close | 1.890 |
| Day's Range | 1.825 - 1.977 |
| 52-Week Range | 0.910 - 2.465 |
| Beta | 2.14 |
| Analysts | Buy |
| Price Target | 5.39 (+192.94%) |
| Earnings Date | May 13, 2026 |
About FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tum... [Read more]
Financial Performance
In 2025, Fate Therapeutics's revenue was $6.65 million, a decrease of -51.24% compared to the previous year's $13.63 million. Losses were -$136.32 million, -26.82% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for FATE stock is "Buy." The 12-month stock price target is $5.39, which is an increase of 192.94% from the latest price.
News
Fate Therapeutics assumed with a Buy at Jefferies
Jefferies assumed coverage of Fate Therapeutics (FATE) with a Buy rating and $4 price target Lead program FAT819 is in Phase 1 for various autoimmune diseases, notes the analyst, who…
Fate Therapeutics reports Q1 EPS (26c), consensus (28c)
Reports Q1 revenue $1.3M, consensus $1.55M. “We are incredibly excited and focused on initiating RECLAIM-LN, our Phase 2 potentially registrational clinical trial of FT819 for the treatment of lupus n...
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initia...
Fate Therapeutics Earnings release: Q1 2026
Fate Therapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Fate Therapeutics Quarterly report: Q1 2026
Fate Therapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major ...
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with expedited clinical development t...
Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent st...
Fate Therapeutics price target raised to $7 from $5 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Fate Therapeutics (FATE) to $7 from $5 and keeps a Buy rating on the shares. The firm says FT819 continues to demonstrate…
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent st...
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent ...
Fate Therapeutics Proxy statement: Proxy filing
Fate Therapeutics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Fate Therapeutics Proxy statement: Proxy filing
Fate Therapeutics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Fate Therapeutics announces data presentation of FT839
Fate Therapeutics (FATE) announced that preclinical data from the Company’s next-generation, off-the-shelf CAR T-cell product candidate, FT839, will be featured at the American Association for Cancer ...
Fate Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Presenters highlighted the scalability and accessibility of iPSC-derived CAR T-cell therapies, with FT819 showing strong safety and efficacy in SLE and lupus nephritis. Next-generation products aim to expand into solid tumors and complex autoimmune diseases, with key data updates expected at EULAR and ACR.
Fate Therapeutics Transcript: Leerink Global Healthcare Conference 2026
FT819, an off-the-shelf CAR T-cell therapy, is advancing in lupus nephritis with strong early efficacy and safety data, outpatient administration, and scalable manufacturing. A pivotal phase II trial is planned for the second half of the year, while next-generation multiplex-edited products are in development for broader autoimmune indications.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent ...
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent ...
Fate Therapeutics reports Q4 EPS (77c), consensus (27c)
Reports Q4 revenue $1.369M, consensus $1.2M. “I am extremely proud of the progress the Fate team delivered in 2025, including bringing to fruition the treatment of FT819 off-the-shelf CAR T…
Fate Therapeutics Earnings release: Q4 2025
Fate Therapeutics released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
Fate Therapeutics Annual report: Q4 2025
Fate Therapeutics has published its Q4 2025 annual report on February 26, 2026.
Fate Therapeutics Annual report: Q4 2025
Fate Therapeutics has published its Q4 2025 annual report on February 26, 2026.
Fate Therapeutics Slides: Corporate presentation
Fate Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on February 26, 2026.
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
The iPSC-derived NK cells clinical trial analysis report delivers important insights into ongoing research of 15+ pipeline iPSC-derived NK cells drugs, clinical strategies, upcoming therapeutics, and ...
Fate Therapeutics presents updated Phase 1 data of FT819
Fate Therapeutics (FATE) presented updated clinical data from its ongoing Phase 1 trial evaluating its FT819 off-the-shelf iPSC-derived CAR T-cell program in systemic lupus erythematosus and unveiled ...